Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease
The results demonstrate the importance of establishing evidence of cost-effectiveness for cholesterol treatment escalation thresholds. The study's findings support the updated NICE guideline recommending a threshold of 2.0 mmol/L LDL-C (or equivalent non-HDL-C of 2.6 mmol/L) for secondary prevention of CVD.
Authors
- Eleanor Samarasekera
- Patrick Muller (ORCID: https://orcid.org/0000-0002-6824-578X)
- Beatrice C. Downing (ORCID: https://orcid.org/0000-0002-7106-1033)
- Joseph Mills (ORCID: https://orcid.org/0000-0002-7373-3980)
- Syed Mohiuddin (ORCID: https://orcid.org/0000-0003-4585-3392)
- David Preiss (ORCID: https://orcid.org/0000-0003-3139-1836)
- Rachael Williams (ORCID: https://orcid.org/0000-0001-9007-6292)
- Nicky J. Welton (ORCID: https://orcid.org/0000-0003-2198-3205)
- Maire Therese Lonergan
- Eduard Shantsila (ORCID: https://orcid.org/0000-0002-2429-6980)
- Riyaz S. Patel (ORCID: https://orcid.org/0000-0003-4603-2393)
- Shaun Rowark
- Alfredo Mariani (ORCID: https://orcid.org/0009-0006-6405-304X)
- David Wonderling (ORCID: https://orcid.org/0000-0003-0315-6273)
- Sharon Swain
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- University of Liverpool (GB)
- Barts Health NHS Trust (GB)
- National Institute for Health and Care Excellence (GB)
- University of Bristol (GB)
- University of Oxford (GB)
- Liverpool Heart and Chest Hospital (GB)
- Clinical Practice Research Datalink (GB)
- University College London (GB)
Publication Details
- Journal
- Applied Health Economics and Health Policy
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1007/s40258-025-00977-6
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00